Clinical trial
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH)…
NCT02069899 · Swedish Orphan Biovitrum, Industry · Completed
Key facts
| NCT number | NCT02069899 |
|---|---|
| Title | A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody |
| Official title | A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody |
| Lead sponsor | Swedish Orphan Biovitrum, Industry |
| Collaborators | Seventh Framework Programme |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hemophagocytic Lymphohistiocytosis |
| Intervention type | Drug |
| Interventions | Emapalumab |
| Enrollment | 58 |
| Start date | Aug 4, 2014 |
| Primary completion | May 18, 2021 |
| Completion | May 18, 2021 |
| First posted | Feb 24, 2014 |
| Last update posted | Jun 28, 2022 |
| Countries | France, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: